halothane

Trade name: fluothane

Small moleculeapproved

Approved

Mar 12, 1958

Halothane, USP is an inhalation anesthetic chemically designated 2-Bromo-2-chloro-1,1,1-trifluoroethane. Halothane, sold under the brand name Fluothane among others, is a general anesthetic. It can be used to start or maintain anesthesia. One of its benefits is that it does not increase the production of saliva which can be particularly useful in those who are difficult to intubate. Side effects include an irregular heartbeat, decreased effort to breath (respiratory depression), and liver problems. It should not be used in people with porphyria or a history of malignant hyperthermia either in themselves or their family members. It is unclear whether use during pregnancy is harmful to the baby, and it is not generally recommended for use during a cesarean section. Fluothane is no longer commercially available in the United States. — NCATS

Clinical trial activity

2 trials · 5 clinical orgs · 4 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Dec 1, 2008 (NCT00815269)

Timeline

1950s

Mar 12, 1958
Wyeth — Earliest FDA Approval
Mar 12, 1958
American Home Products — NDA Secondary Org
Mar 12, 1958
Wyeth — NDA Organization

1970s

May 9, 1972
Halocarbon Products — Marketing Organization
May 30, 1975
Hospira — Marketing Organization

Indications

Approved for

Pain (approved 1958)

Mechanism of action

Approval history

approvedPriority reviewMar 12, 1958

Chemistry & pharmacology

Loading structure…

SMILES

FC(F)(F)C(Cl)Br

Mol. weight: 197.382 g/mol
Lipinski Ro5: Pass
Rule of 3: Yes
Chirality: Racemic Mixture
Inorganic: No
Polymer: No
Delivery: Topical
Availability: Discontinued

Oral

Parenteral

Topical

Yes

Sources

Also known as

1,1,1-trifluoro-2-bromo-2-chloroethane
1,1,1-trifluoro-2-bromo-2-chloroethane
1,1,1-trifluoro-2-chloro-2-bromoethane
1,1,1-trifluoro-2-chloro-2-bromoethane
1-bromo-1-chloro-2,2,2-trifluoroethane
1-bromo-1-chloro-2,2,2-trifluoroethane
2,2,2-trifluoro-1-chloro-1-bromoethane
2,2,2-trifluoro-1-chloro-1-bromoethane
2-bromo-2-chloro-1,1,1-trifluoroethane
2-bromo-2-chloro-1,1,1-trifluoroethane
anestan
bromochlorotrifluoroethane
bromochlorotrifluoroethane
fluothane
fluothane
fluothane
fluothane
ftorotan
ftorotan
ftorotan
halotano
halotano
halothane
halothane
halothane
halothane
halothane
halothane
halothane
halothane
halothane
halothane
halothane
halothanum
halothanum
narcotan
narcotane
narcotane
narcotane
phthorothanum
phthorothanum
rhidialothan
rhodialothan
rhodialothan
rhodialothan

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT05031676	N/A	Feb 15, 2019	CHU Charleroi, CHU Sanou Souro, Bobo-Dioulasso, Université NAZI BONI, University of Joseph KI-ZERBO
NCT00815269	N/A	Dec 1, 2008	Nanjing Medical University

Showing 2 of 2 trials

Page 1 / 1

Organizations

Research & Development (5)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
CHU Charleroi	Academic/Hospital	1	0	1	2019
CHU Sanou Souro, Bobo-Dioulasso	Academic/Hospital	1	0	1	2019
Nanjing Medical University	Academic/Hospital	1	1	1	2008
Université NAZI BONI	Academic/Hospital	1	1	1	2019
University of Joseph KI-ZERBO	Academic/Hospital	1	0	1	2019

5 organizations

Page 1 / 1

Marketing (5)

Organization	Org type	Relationship	Date
American Home Products	For profit	NDA2	Mar 12, 1958
Halocarbon Products	For profit	MKTG	May 9, 1972
Hospira	For profit	MKTG	May 30, 1975
Hospira	For profit	SYN	Jul 14, 1976
Wyeth	For profit	NDA	Mar 12, 1958